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Essential hypertension has devastating effects on the brain, being the major cause of stroke and a leading
cause of dementia. Hypertension alters the structure of cerebral blood vessels and disrupts intricate vaso-
regulatory mechanisms that assure an adequate blood supply to the brain. These alterations threaten the
cerebral blood supply and increase the susceptibility of the brain to ischemic injury as well as Alzheimer’s
disease. This review focuses on the mechanisms by which hypertension disrupts cerebral blood vessels,
highlighting recent advances and outstanding issues.Introduction
Hypertension is one of the major health problems of the Western
world. Hypertension, defined as elevation in blood pressure
above 140 mm Hg systolic or 90 mm Hg diastolic, afflicts 25%
of the general population and is the premier risk factor for serious
diseases affecting the brain, heart, and kidneys (Messerli et al.,
2007). Although much is known about the mechanisms control-
ling blood pressure, a specific cause for hypertension can be
ascertained in only a minority of patients. Therefore, in most in-
stances, a cause for the elevated blood pressure cannot be
found, hence the term ‘‘essential hypertension.’’ Fortunately,
a wide variety of treatments are available to lower blood pres-
sure, and their use has reduced the disease burden caused by
hypertension (Messerli et al., 2007). Furthermore, a better under-
standing is emerging of how hypertension induces damage in
susceptible organs, raising the possibility of organ-specific ther-
apies (Messerli et al., 2007).
The brain is a major target of the deleterious effects of hyper-
tension and is responsible for a large portion of the related mor-
tality and morbidity (Dahlof, 2007). Hypertension is the number
one risk factor for stroke and is a leading cause of cognitive
decline and dementia (Dahlof, 2007) (Figure 1). There is a linear
relationship between blood pressure and stroke mortality, and
in patients with treated hypertension, a 1 mmHg increase in sys-
tolic blood pressure increases stroke deaths by 2% (Palmer
et al., 1992). Furthermore, hypertension is a powerful risk factor
for Alzheimer’s disease (Figure 1), the most common cause of
dementia in the elderly (Kelley and Petersen, 2007). Recent
advances in neurovascular regulation and in the pathobiology
of hypertension have led to a deeper understanding of how
hypertension disrupts the cerebral blood supply. These new
findings provide the opportunity for the present reappraisal of
the cerebrovascular effects of hypertension.
The Cerebral Blood Supply
The intracranial cerebral arteries take off from the circle of Willis
at the base of the brain and give rise to progressively smaller ves-
sels traveling on the brain surface. These surface vessels,
termed pial arteries, branch out into smaller vessels, which pen-
etrate into the substance of the brain and give rise to arterioles476 Cell Metabolism 7, June 2008 ª2008 Elsevier Inc.and capillaries. Like elsewhere in the body, brain blood vessels
are lined with endothelial cells. Arteries and arterioles have one
or more layers of smooth muscle cells (myocytes), contractile
cells that regulate vascular diameter. In capillaries, myocytes
are replaced by pericytes. Cerebral arteries and arterioles are
innervated by nerve fibers arising from cranial autonomic and
sensory ganglia (Iadecola and Nedergaard, 2007). Smaller arte-
rioles (%100 mm) and capillaries are fully enveloped by the end-
feet processes of astrocytes (Iadecola and Nedergaard, 2007).
Owing to the blood-brain barrier (BBB), cerebral capillaries are
impermeable to most blood-borne substances (Zlokovic, 2008).
Unlike other organs, extraparenchymal arteries and arterioles
account for 2/3 of the vascular resistance, while intracerebral
arterioles and capillaries account for the remaining 1/3 (Faraci
and Heistad, 1990). Therefore, vessels residing outside of the
brain have the greatest impact on parenchymal blood flow.
Adaptive Responses of the Cerebral Circulation
The brain has limited fuel reserves, and its integrity depends on
a continuous supply of oxygen and energy substrates delivered
through blood flow. Thus, cerebral blood vessels are endowed
with adaptive mechanisms that assure that the brain receives
an adequate amount of blood at all times (Figure 2). The major
control mechanisms relevant to the cerebrovascular effects of
hypertension are briefly examined below.
Functional Hyperemia
The cerebral blood supply is regionally heterogeneous, reflecting
the varying energetic needs of different brain regions. When
a brain region is activated, cerebral blood flow (CBF) in that par-
ticular region increases, a phenomenon termed functional hyper-
emia (for review, see Iadecola and Nedergaard, 2007). Accumu-
lating evidence suggests that neurons, astrocytes, and vascular
cells release a multitude of vasoactive agents that act in concert
to produce vasodilatation of local arterioles during neural activ-
ity. These agents include mainly nitric oxide (NO), carbon mon-
oxide, prostanoids, cytochrome p450 metabolites, adenosine,
and K+ ions (Iadecola and Nedergaard, 2007). The vasodilatation
of local arterioles is accompanied by vasodilatation of upstream
pial arteries that supply the activated area. The coordinated
vasodilatation of intraparenchymal arterioles and pial arterioles
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cellular communication between vascular cells or astrocytes
(Iadecola and Nedergaard, 2007).
Cerebrovascular Autoregulation
Cerebrovascular autoregulation renders CBF independent of
changes in arterial pressure within a certain range, 60–150 mm
Hgmeanarterial pressure (Cipolla, 2007;Paulson et al., 1990) (Fig-
ure 2; see also below). Arterial pressure varies markedly during
normal daily activities (Mancia et al., 1988), and these changes
may lead to potentially dangerous increases or decreases in
CBF. To counteract the effects of blood pressure variations on
CBF, cerebral arterioles adjust their resistance according to intra-
vascular pressure. Thus, arterioles constrict when the pressure in-
creases and relaxwhen the pressure decreases. Autoregulation is
related to theabilityofarterialmyocytes toconstrictwhen intravas-
cular pressure rises (myogenic response) (Brayden et al., 2008).
The myogenic response stems from the fact that an increase in
intravascular pressure depolarizes arterial myocytes, leading to
Ca2+ influx and vasoconstriction (Brayden et al., 2008). In addition
to Ca2+ influx, Ca2+ sensitization of the smoothmuscle contractile
apparatus via protein kinase C (PKC) and Rho kinase also plays
a role (Brayden et al., 2008; Chrissobolis and Sobey, 2006).
Figure 1. Hypertension, Stroke, and Dementia
Hypertension has a key role in twomajor brain pathologies, stroke and demen-
tia. Stroke can result from occlusion of a major cerebral artery (ischemic
infarct) or rupture of intracerebral arterioles (hemorrhage). Hypertension also
causes rupture of berry aneurysms of the circle of Willis, leading to bleeding
into the subarachnoid space (subarachnoid hemorrhage). Ischemia can lead
to hemorrhage by rupture of ischemic vessels or extravasation of blood from
leaky blood vessels. Conversely, hemorrhage can lead to ischemia by com-
pressing the surrounding areas and reducing local blood flow. Vascular cogni-
tive impairment (VCI) is caused by occlusion of small arterioles in the subcor-
tical white matter, which interrupt neural connections subserving cognition
and memory (Chui, 2007). A single stroke can lead to dementia by interrupting
circuits involved in memory and cognition, such as the midline thalamus (stra-
tegic infarct dementia, SID). Multiple strokes can cause dementia by produc-
ing cumulative brain damage (multi-infarct dementia, MID). Hypertension is
a risk factor for Alzheimer’s disease, a progressive dementia caused by accu-
mulation of b-amyloid (Staessen et al., 2007).While vascular dementia and Alz-
heimer’s disease have traditionally been considered separate entities, recent
evidence suggests that they share common and interacting pathogenic factors
(Iadecola, 2004).Endothelial Regulation
Cerebral endothelial cells exert powerful effects on vascular tone
by releasing vasodilators (NO, prostacyclin, bradykinin, etc.) and
vasoconstrictors (endothelin, endothelium-derived constrictor
factor, etc.) (Andresen et al., 2006). Endothelium-derived vaso-
active factors participate in the maintenance of resting vascular
tone and may play a role in coordinating the vasodilatation of in-
traparenchymal arterioles with that of upstream pial arteries, and
in local adjustments of flow in response to mechanical forces
(Andresen et al., 2006; Iadecola, 2004).
Hypertension Alters the Structure
of Cerebral Blood Vessels
Atherosclerosis and Lipohyalinosis
Hypertension promotes formation of atherosclerotic plaques in
cerebral arteries and arterioles, which may lead to arterial occlu-
sions and ischemic injury (Dahlof, 2007; Lammie, 2002) (Figure 3).
In addition, hypertension induces fibrinoid necrosis (lipohyalino-
sis) of penetrating arteries and arterioles supplying the white
matter, resulting in small white matter infarcts (lacunes) or brain
hemorrhage (Lammie, 2002) (Figure 3).
Hypertrophy, Remodeling, and Stiffening
Hypertension induces adaptive changes in systemic and cere-
bral arteries known as hypertrophic and eutrophic remodeling.
In hypertrophic remodeling, smoothmuscle cells undergo hyper-
trophy or hyperplasia and grow inward, encroaching into the lu-
men of the artery. This process increases the wall thickness and
reduces the lumen of the vessel (Baumbach and Heistad, 1988).
In eutrophic remodeling, smooth muscle cells undergo a rear-
rangement that leads to a reduction of the vessel lumen without
changes in total vascular mass or wall thickness (Baumbach and
Heistad, 1988). Hypertension also leads to vascular stiffening,
a process that increases collagen content and rigidity of the
vessel wall (Baumbach and Heistad, 1988).
Several factors contribute to hypertrophy in cerebral arteries
and arterioles. The sympathetic perivascular innervation, which
exerts a trophic effect on the vascular wall, is required for the
development of cerebrovascular hypertrophy (Baumbach et al.,
1989). Furthermore, mechanical effects of the elevated intravas-
cular pressure on the vascular wall play a role through growth
factors, oxidative stress, and NO (Harrison et al., 2006; O’Calla-
ghan and Williams, 2000). Reduced availability of NO, an agent
with antiproliferative activity, leads to hypertrophy, as indicated
by the vascular growth observed with nitric oxide synthase
(NOS) inhibition or in eNOS/ mice (Table 1). Interestingly, in
eNOS/ mice, which have elevated blood pressure, hypertro-
phy persists even if the increase in cerebrovascular pressure
ispreventedby ligationof the ipsilateral carotid artery (Baumbach
et al., 2004). Furthermore, in mice lacking the homocysteine
metabolism enzyme cystathionine b-synthase or the reactive
oxygen species (ROS) scavenger enzyme Cu/Zn superoxide
dismutase (SOD1), hypertrophy develops in the absence of
hypertension (Table 1). Therefore, hypertrophy can occurwithout
elevations in intravascular pressure, indicating that mechanical
effects on the vascular wall are not an absolute requirement.
Angiotensin II (AngII) has emerged as a key factor in the mech-
anisms of cerebrovascular remodeling (Schiffrin and Touyz,
2004). Treatment of spontaneously hypertensive rats with
angiotensin-converting enzyme inhibitors attenuates remodelingCell Metabolism 7, June 2008 ª2008 Elsevier Inc. 477
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bach, 1999). Hypertensive mice overexpressing human renin
and angiotensinogen (R+/A+) exhibit both hypertrophy and re-
modeling, whereas BPH-2 mice, in which hypertension is not re-
lated to AngII, exhibit only hypertrophy (Table 1). ROS participate
in the remodeling of cerebral blood vessels induced by AngII
Figure 3. Effects of Hypertension on the Cerebral
Blood Vessels
Hypertension induces structural and functional alterations in
cerebral blood vessels, which compromise the blood supply
to the brain and increase the risk of stroke and dementia.
See text for details.
Figure 2. The Neurovascular Unit
and Adaptive Responses of the
Cerebral Circulation
Neurons, astrocytes, myocytes, and endothelial
cells act in concert to maintain an adequate cere-
bral perfusion. Functional hyperemia increases
cerebral blood flow (CBF) when neural activity
increases. Cerebrovascular autoregulation main-
tains CBF stability during variations in arterial
pressure within a certain range. Although not
shown in this figure, larger cerebral arteries also
contribute to autoregulation (see text). Endothelial
cells release potent vasodilator and constrictor
agents in response to chemical and mechanical
signals.
(Schiffrin and Touyz, 2004). ROS also
promote smooth muscle cell proliferation
and initiate remodeling of the extracellu-
lar matrix via activation of matrix metallo-
proteases (MMPs) (Flamant et al., 2007).
Extracellular matrix proteins play a crit-
ical role in hypertrophy, remodeling, and
stiffening. AngII-induced hypertension is
associated with activation of MMP and
breakdown of matrix proteins (Flamant
et al., 2007). Antagonists of the integrin
anb3 prevent arterial remodeling in mesenteric arteries of re-
nin-overexpressing rats (Heerkens et al., 2007). In addition,
mice lacking elastin-1 develop vascular stiffening and hyperten-
sion (Faury et al., 2003). Similarly, deficiency of the vascular
matrix protein emilin-1 leads to increased vascular resistance
andhypertension (Zacchignaet al., 2006). Therefore,mechanical,478 Cell Metabolism 7, June 2008 ª2008 Elsevier Inc.
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Mouse Model Relevant Phenotype Hypertrophy Remodeling Reference
BPH-2 strain Renin-independent HTN +  Baumbach et al. (2003)
L-NAME treatment NO-deficiency HTN +  Baumbach et al. (2004)
eNOS/ Endothelial NO deficiency HTN +  Baumbach et al. (2004)
SOD1+/ Increased oxidative stress +  Baumbach et al. (2006)
CBS+/ Increased plasma homocysteine +  Baumbach et al. (2002)
R+/A+ transgenics AngII-dependent HTN + + Baumbach et al. (2003)
PPARG dominant-negative
in smooth muscle
Vascular dysregulation HTN + + Halabi et al. (2008)
Abbreviations: HTN, hypertension; L-NAME, L-arginine methyl ester; eNOS, endothelial nitric oxide synthase; SOD1, superoxide dismutase; CBS,
cystathionine b-synthase; R+/A+, renin and angiotensinogen; PPARG, peroxisome proliferator-activated receptor g (PPARg).neural, and humoral factors contribute to the changes in cerebro-
vascular wall structure and composition induced by hyperten-
sion.
Hypertrophy and remodeling are adaptive responses aimed at
reducing stress on the vessel wall and protecting downstream
microvessels from the effect of increased pressure (Baumbach
and Heistad, 1988; Laurent et al., 2005). Failure of this protective
mechanism leads to BBB alterations, cerebral edema, and cere-
brovascular pathology. Thus, ablation of perivascular sympa-
thetic nerves early in life prevents cerebrovascular hypertrophy
in stroke-prone spontaneously hypertensive rats and promotes
the development of cerebrovascular lesions (Sadoshima et al.,
1983). Similarly, the cerebrovascular alterations associated
with eclampsia may be related to the lack of hypertrophy or
remodeling during pregnancy (Cipolla, 2007). On the other
hand, remodeling of systemic or cerebral vessels is potentially
damaging because it reduces the vessel’s lumen and increases
vascular resistance, resulting in a greater propensity for vascular
insufficiency (Barry, 1985; Mathiassen et al., 2007) (see below).
Arterial stiffening is also deleterious because it leads to increases
in pulse pressure, a good predictor of stroke and cognitive
impairment (Benjo et al., 2007; Waldstein et al., 2008).
The relationships among stiffening, hypertrophy, and remodel-
ingarepoorlyunderstood (Laurentet al., 2005).Cerebral arterioles
undergoing hypertrophy or remodeling have reduced stiffening
(Baumbach et al., 2003; Chillon and Baumbach, 1999). However,
if hypertension is sustained, the changes in vascular wall compo-
sition may lead to reduced distensibility and stiffening (Izzard
et al., 2006). Therefore, duration andmagnitude of theblood pres-
sure elevation as well as vessel size are important determinants
of the alteration in the vascular wall induced by hypertension.
In summary, hypertension has profound effects on the struc-
ture of cerebral blood vessels. While atherosclerosis and lipo-
hyalinosis may lead to vascular occlusions, rearrangement of
the cellular architecture and changes in the composition of the
vascular wall alter the mechanical and hemodynamic properties
of the vessels. The functional implications of these structural
changes are examined in the next section.
Hypertension Alters Resting CBF and Disrupts Adaptive
Responses of the Cerebral Circulation
Alterations in Resting CBF and Functional Hyperemia
Cross-sectional studies of CBF in hypertensive patients have
usually reported unchanged or slightly reduced resting CBF, re-flecting an autoregulatory increase in cerebrovascular resistance
to counteract the increase in perfusion pressure and keep CBF
constant (Jennings et al., 2005; Kety et al., 1948; Matsushita
et al., 1994). However, longitudinal studies have shown reduc-
tions in CBF in selected brain regions (Beason-Held et al.,
2007). The CBF reductions often precede cerebrovascular
symptoms or white matter lesions (O’Sullivan et al., 2002). CBF
reductions have also been observed in stroke-prone spontane-
ously hypertensive rats just prior to developing brain infarcts
(Mies et al., 1999). The CBF reductions are likely to result from
a combination of factors, including aging, reduced brain activity,
and vascular narrowing, as well as increased vascular tone
secondary to endothelial dysfunction (Barry, 1985; Mentis et al.,
1994; Park et al., 2007). Hypertension also alters functional hy-
peremia. The increase in CBF induced by brain activation is at-
tenuated in patients with chronic hypertension (Jennings et al.,
2005). The cerebrovascular dysfunction correlates with cognitive
deficits (Jennings et al., 2005). In mice in which AngII is adminis-
tered systemically for 30 min or 7 days, the increase in CBF in-
duced by activation of the somatosensory cortex by stimulation
of the facial whiskers is markedly attenuated (Kazama et al.,
2003). The attenuation is not dependent on the elevation in blood
pressure, because application of AngII to the somatosensory
cortex attenuates functional hyperemia without inducing hyper-
tension (Kazama et al., 2003). Therefore, the effects of AngII on
functional hyperemia can occur independently of elevations in
blood pressure.
Endothelial Dysfunction
Hypertension alters endothelium-dependent relaxation of cere-
bral blood vessels. The increase in CBF produced by neocortical
application of endothelium-dependent vasodilators is attenu-
ated in spontaneously hypertensive rats, in R+/A+ mice, or in
wild-type mice infused systemically with AngII (Didion et al.,
2000; Kazama et al., 2003; Yang et al., 1991). In contrast, re-
sponses mediated by the smooth muscle relaxants adenosine
and nitroprusside are not attenuated (Didion and Faraci, 2003;
Kazama et al., 2003), indicating that the deficit of vasodilation
is not due to a nonspecific reduction in vascular reactivity or to
smooth muscle dysfunction. Altered responses to acetylcholine
have also been reported in the vertebral artery of hypertensive
patients (Charpie et al., 1996).
Impairment of Autoregulation
Hypertension alters cerebrovascular autoregulation, leading to
a shift of the pressure-flow curve to the right (Figure 4A) (PaulsonCell Metabolism 7, June 2008 ª2008 Elsevier Inc. 479
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pressures are needed to maintain the same level of CBF
(Figure 4A). Studies using transcranial Doppler to measure mid-
dle cerebral artery flow velocity have shown that transient
changes in blood pressure still elicit compensatory flow adjust-
ments (Traon et al., 2002), indicating that the ability of cerebral
vessels to adapt to dynamic pressure changes may be pre-
served despite the shift of the pressure-flow curve. The shift in
autoregulation is related to the increase in myogenic tone
induced by an increase in Ca2+ sensitivity of myocytes (Chris-
sobolis and Sobey, 2006). Remodeling and hypertrophy also
contribute to the shift in autoregulation by reducing the vascular
Figure 4. Effect of Hypertension on Cerebrovascular Autoregulation
and Peroxynitrite Production
(A) Cerebrovascular autoregulation. CBF is maintained relatively constant de-
spite changes in arterial pressure within a certain range (60–150 mm Hg mean
arterial pressure). Hypertension shifts the curve to the right, so that higher
levels of blood pressure are needed to maintain CBF in the autoregulated
range.
(B) Peroxynitrite production mediates cerebrovascular dysfunction by AngII.
Peroxynitrite (PN) formed from NADPH-derived superoxide and nitric oxide
(NO) induces vascular dysfunction through different mechanisms (see Pacher
et al., 2007 for references): (1) PN opposes vasodilation by removing NO and
by inhibiting prostacyclin synthase, the enzyme that produces prostacyclin; (2)
PN nitrates the tissue plasminogen activator (tPA) and attenuates its proteo-
lytic activity (Nielsen et al., 2004); (3) PN exacerbates oxidative stress by inhib-
iting superoxide dismutase (SOD) and by altering nitric oxide synthase (NOS)
to produce superoxide instead of NO (NOS uncoupling); (4) PN induces DNA
damage, leading to overactivation of the DNA repair enzyme poly(ADP-ribose)
polymerase, resulting in NAD depletion and energy deficit; (5) PN inactivates
mitochondrial enzymes and alcohol dehydrogenase and can inducemetabolic
stress.480 Cell Metabolism 7, June 2008 ª2008 Elsevier Inc.lumen and increasing cerebrovascular resistance (Barry, 1985;
Baumbach and Heistad, 1988). Alterations in autoregulation in-
crease the susceptibility of the brain to cerebral ischemia when
blood pressure drops because cerebral blood vessels fail to
compensate for the reduction in perfusion pressure (Immink
et al., 2004). The periventricular white matter is most susceptible
to ischemic damage because it is located at the boundary
between two arterial territories: penetrating arteries reaching
down from the brain surface and basal ganglia arteries arising
from the base of the brain (De Reuck, 1971). In hypertensive
patients, the severity of periventricular white matter injury, or
leukoaraiosis, correlates with the magnitude of autoregulatory
dysfunction (Matsushita et al., 1994) and with cognitive impair-
ment as well (Chui, 2007). Impaired autoregulation also leads
to more severe ischemia after arterial occlusion. Thus, middle
cerebral artery occlusion in spontaneously hypertensive rats
leads to larger infarcts than in normotensive rats (Nishimura
et al., 2000).
To summarize, the alterations in functional hyperemia, autore-
gulation, and endothelial function induced by hypertension act in
concert with the structural alterations of cerebral blood vessels
to reduce the compensatory capacity of the cerebral circulation
and increase the susceptibility of the brain to vascular insuffi-
ciency (Figure 3).
Oxidative Stress Is a Critical Factor
in the Cerebrovascular Effects of Hypertension
Increasing evidence suggests that oxidative stress is involved in
the deleterious effects of hypertension. In humans, systemic
markers of oxidative stress are increases in essential hyperten-
sion, renovascular hypertension, malignant hypertension, and
preeclampsia (Touyz, 2004). Oxidative stress in brain and cere-
bral blood vessels plays a central role in the mechanisms of
hypertension and its cerebrovascular effects. In models of hy-
pertension, ROS production is elevated in central autonomic re-
gions implicated in blood pressure control (for review, see Peter-
son et al., 2006). ROS production within these brain regions
contributes to the neurohumoral changes that drive the hyper-
tension (Peterson et al., 2006). In addition, hypertension induces
oxidative stress in cerebral blood vessels. In models of AngII-
induced hypertension, ROS production increases in large and
small cerebral vessels, including pial arterioles (Didion et al.,
2005; Girouard et al., 2006, 2007; Kazama et al., 2004). Free rad-
ical scavengers prevent the effects of hypertension on functional
hyperemia and endothelium-dependent responses, indicating
that the cerebrovascular dysfunction ismediated by ROS (Didion
et al., 2005; Girouard et al., 2006; Kazama et al., 2004).
NADPH Oxidase as a Source of ROS
There are several potential sources of ROS in cerebrovascular
cells, including mitochondrial enzymes, xanthine/xanthine oxi-
dase, and NOS uncoupling, a condition in which NOS produces
superoxide instead of NO (Faraci, 2006). However, the enzyme
NADPH oxidase has emerged as a major source of the ROS
mediating cerebrovascular dysfunction. NADPH oxidase is a
multiunit enzyme initially discovered in phagocytes that is also
present in vascular cells and is particularly enriched in cerebral
blood vessels (Miller et al., 2005). The enzyme is comprised of
membrane-bound (p22phox and Nox) and cytoplasmic subunits
(p47phox and p67phox) and requires the small GTPase Rac for
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homologs, Nox1–5, and is the catalytic site of the enzyme (Be-
dard and Krause, 2007). Nox1, 2, and 4 are present in cerebral
blood vessels (Ago et al., 2005; Kazama et al., 2004; Miller
et al., 2005). Activation of AngII AT1-type receptors leads to ac-
tivation of phospholipase C, which increases cytoplasmic Ca2+
and activates PKC (Bedard and Krause, 2007). PKC in turn
phosphorylates p47phox, leading to the assembly of the enzyme
and ROS production (Bedard and Krause, 2007). NADPH
oxidase-derived ROS have been implicated in the cerebrovascu-
lar dysfunction induced by AngII. Mice lacking Nox2 do not
exhibit cerebrovascular oxidative stress and are protected
from the alterations in endothelium-dependent relaxation and
functional hyperemia induced by AngII (Girouard et al., 2006;
Kazama et al., 2004). Furthermore, a peptide inhibiting the as-
sembly of NADPH oxidase or a pharmacological inhibitor of
this enzyme blocks the ROS production and cerebrovascular
dysfunction induced by AngII (Didion and Faraci, 2003; Girouard
et al., 2006).
Peroxynitrite and Cerebrovascular Dysfunction
One prominent pathway through which ROS alter vascular regu-
lation involves formation of peroxynitrite, the product of the reac-
tion betweenNOand the radical superoxide (Pacher et al., 2007).
Peroxynitrite exerts powerful biological effects by inducing DNA
damage and lipid peroxidation and by altering protein function
through interaction with transition metal centers, tyrosine nitra-
tion, and cysteine oxidation (Pacher et al., 2007). Peroxynitrite
can have deleterious effects on cerebral blood vessels (Faraci,
2006) (Figure 4B). Recent evidence suggests that peroxynitrite
is critical for the cerebrovascular dysfunction induced by AngII.
Systemic administration of AngII produces marked nitration
of cerebral arterioles, which depends on NO and NADPH
oxidase-derived superoxide (Girouard et al., 2007). Inhibition of
nitration with a peroxynitrite decomposition catalyst or with the
peroxynitrite inactivator uric acid prevents the cerebrovascular
dysfunction induced by AngII (Girouard et al., 2007). The obser-
vation that AngII does not induce vascular nitration and cerebro-
vascular dysfunction in eNOS/mice points to the endothelium
as the main source of NO responsible for peroxynitrite formation
(Girouard et al., 2007). Another pathway through which AngII
could induce vascular dysfunction involves the tissue plasmino-
gen activator (tPA). In addition to its role in intravascular fibrino-
lysis, tPA is a powerful neuromodulator that is critical for NMDA
receptor signaling (Samson and Medcalf, 2006). tPA contributes
to functional hyperemia by regulating the coupling between
NMDA receptor activity and neuronal NO production (Park
et al., 2008a). AngII counteracts the biological effect of tPA by
upregulating the expression of its endogenous inhibitor plasmin-
ogen activator inhibitor-1 (PAI-1) (Chen and Feener, 2004). In ad-
dition, peroxynitrite attenuates tPA proteolytic activity (Nielsen
et al., 2004), providing an additional pathway through which
AngII-induced peroxynitrite could impair vascular regulation
(Figure 4B).
In summary, ROS are keymediators of the cerebrovascular ef-
fects of hypertension. They participate in the structural remodel-
ing of cerebral blood vessels and in the functional alterations
induced by hypertension. Some of these effects are mediated
by vascular nitrosative stress induced by peroxynitrite derived
from NADPH oxidase-derived superoxide and NO.Hypertension and Alzheimer’s Disease
Alzheimer’s disease (AD) has traditionally beenconsideredaneu-
rodegenerative condition caused by neuronal dysfunction result-
ing from brain accumulation of b-amyloid (amyloid plaques) and
neuronal cytoskeletal abnormalities (neurofibrillary tangles) (Kel-
ley andPetersen, 2007). However, epidemiological, pathological,
and experimental evidence suggests that vascular factors, in-
cluding hypertension, play a significant role in the pathogenesis
of AD (for review, see Iadecola, 2004). In particular, midlife hyper-
tension increases the risk of AD later in life and accelerates the
progression of AD (for review, see Skoog and Gustafson, 2006).
Furthermore, brain atrophy, amyloid plaques, and neurofibrillary
tangles are increased in the brain of patientswith a history ofmid-
life hypertension (Skoog and Gustafson, 2006). AD patients have
white matter lesions resembling those associated with hyperten-
sion, and if these lesions coexist with amyloid plaques, they pro-
duce cognitive deficits greater than those predicted based on the
AD pathology alone (Sheng et al., 2007; Snowdon et al., 1997). A
proportion of patients with AD also have ischemic brain lesions,
and AD patients havemore severe atherosclerosis in cerebral ar-
teries than nondemented controls (Roher et al., 2003; Skoog and
Gustafson, 2006). Studies in mouse models of AD have demon-
strated that b-amyloid disrupts the function of cerebral blood
vessels (Iadecola, 2004). b-amyloid attenuates functional hyper-
emia and endothelium-dependent responses (Iadecola et al.,
1999; Niwa et al., 2000) and impairs cerebrovascular autoregula-
tion (Niwa et al., 2002). Interestingly, the mechanisms of b-amy-
loid-induced cerebrovascular dysfunction are similar to those
of AngII and involve NADPH oxidase-derived ROS. Thus, mice
lacking Nox2 are protected from the deleterious cerebrovascular
and cognitive effects of brain b-amyloid accumulation (Park et al.,
2008b). Hypertension could promote AD by increasing the pro-
duction of the b-amyloid peptide. This possibility is supported
by the finding that cerebral hypoxia-ischemia, which can occur
with hypertension, facilitates the cleavage of b-amyloid from its
precursor protein and increases the brain’s b-amyloid burden
(Sun et al., 2006). Furthermore, the brain deposition of circulating
b-amyloid is increased in models of hypertension, suggesting
another mechanism by which hypertension could increase brain
b-amyloid (Gentile et al., 2007). However, in the years immedi-
ately preceding the onset of dementia, blood pressure begins
to decrease in AD patients, and it continues to decline during
the course of the illness (Skoog and Gustafson, 2006). Because
autoregulation is impaired by b-amyloid, hypotension is likely to
cause cerebral hypoperfusion, which in turn can enhance b-
amyloid cleavage and deposition (Bennett et al., 2000).
The biological bases of the reciprocal interaction between AD
and hypertension remain unclear. It is unlikely that AD pathology,
e.g., plaques and tangles, causes the elevation in arterial pres-
sure, because hypertension occurs decades before the onset
of symptoms. Although AD has a long presymptomatic period,
this preclinical phase is not likely to span several decades (Kelley
and Petersen, 2007). Therefore, hypertension may precede AD
pathology and, as such, could have a role in the pathogenesis
of the disease. On the other hand, the reduction in arterial pres-
sure that occurs when AD is fully developed is more likely to be
related to pathological changes in central autonomic nuclei
controlling blood pressure, such as the C1 area of the rostral
ventrolateral medulla (Burke et al., 1994). The dehydration,Cell Metabolism 7, June 2008 ª2008 Elsevier Inc. 481
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severe dementia could also contribute to the decrease in blood
pressure (Skoog and Gustafson, 2006). Therefore, while hyper-
tension may promote the development of amyloid plaques early
in the course of the disease, the pathological changes induced
by AD lead to a reduction in arterial pressure in the late phase.
The hypotension may in turn produce hypoxia-ischemia, which
acts synergistically with AD pathology to worsen the dementia.
Challenges and Opportunities
Great progress has beenmade in understanding the biological ba-
ses of hypertension and the mechanisms underlying its powerful
effects on the brain circulation. Although these developments
have unveiled newavenues for the treatment of the devastating ef-
fects of hypertension on the brain, they also have raised newques-
tions that remain tobeaddressed.Forexample, theeffectsofblood
pressurecontrol onstroke risk arewell documented, andemerging
data suggest that controlling blood pressure reverses some of the
effects of hypertension on cerebral blood vessels and ameliorates
cognition (Peila et al., 2006). Therefore, treatment of elevatedblood
pressure remains themainstayofpreventiveapproaches toprotect
the brain and other organs from hypertension (Dahlof, 2007; Mes-
serli et al., 2007). In addition, considering the role of hypertension
in b-amyloid neuropathology, controlling hypertension may be
valuable for AD prevention as well (Skoog and Gustafson, 2006).
However, questions remain about the ‘‘ideal’’ blood pressure that
shouldbeachieved in hypertensivepatients. The linear relationship
between stroke mortality and blood pressure suggests that the
lower the value, the better the outcome, but excessive lowering
of diastolic blood pressure may increase the incidence of periven-
tricular white matter lesions (van Dijk et al., 2004). This is clearly an
area that requires further investigation.
Another question concerns whether all blood pressure-lower-
ing agents are equivalent or whether specific agents may afford
brain protection beyond that achieved by their antihypertensive
effect. In clinical trials, angiotensin-converting enzyme inhibitors
or AT1 receptor antagonists conferred greater protection against
strokeordementia than treatmentwithother agentsdespite com-
parable blood pressure lowering (Dahlof, 2007; Messerli et al.,
2007). This finding is consistent with the experimental observa-
tion that some of the cerebrovascular effects of AngII are inde-
pendent of the blood pressure elevation (Chillon and Baumbach,
1999; Kazama et al., 2003), raising the possibility that the delete-
rious effects of AngII on the cerebral circulation are not secondary
to theeffect of this peptideonsystemicbloodpressure.However,
some studies have not observed a benefit of agents targeting the
renin-angiotensin system versus other antihypertensive treat-
ments (Messerli et al., 2007; Staessen et al., 2007). Therefore,
more data are needed on the effects of antagonists of the renin-
angiotensin system and other antihypertensive agents in the pre-
vention of the cerebral complications of hypertension. Interest-
ingly, the AT1 receptor antagonist valsartan reduces amyloid
plaques in amousemodel of AD and improves behavioral perfor-
mance without altering arterial pressure (Wang et al., 2007). Fur-
thermore, Rho kinase inhibitors and statins could also have a role
in the treatment of the deleterious effects of hypertension on the
brain (Chrissobolis and Sobey, 2006). Like AT1 receptor inhibi-
tors, these agents are attractive because they also have neuro-
protective effects against ischemia and b-amyloid pathology482 Cell Metabolism 7, June 2008 ª2008 Elsevier Inc.(Chrissobolis and Sobey, 2006; Mueller et al., 2005). Therefore,
thechoiceof antihypertensiveagentsusedmayalsobe important
in the prevention of stroke and dementia.
Animal studies have demonstrated that ROS have a prominent
role in the pathogenic effects of hypertension on the brain and
other organs, yet free radical scavengers have failed to provide
a benefit in cardiovascular diseases and stroke (Griendling and
FitzGerald, 2003). The finding that NADPH oxidase is the major
source of the ROS involved in the cerebrovascular effects of hy-
pertension suggests that treatments targeting this enzyme could
be effective. However, in light of the role of NADPH oxidase in
immune defense, chronic inhibition of NADPH oxidase is not a
viable strategy. Thus, approaches to selectively inhibit NADPH
oxidase-dependent ROS production in vascular cells need to
be developed. A greater understanding of the cellular andmolec-
ular features of vascular NADPH oxidase is needed to develop
pharmacological strategies for its selective inhibition.
The fact that peroxisome proliferator-activated receptor g
(PPARg) may serve as an endogenous cerebrovasoprotective
system (Halabi et al., 2008) suggests that PPARg activators,
such as thiazolidinediones used in the treatment of type 2 diabe-
tes, could have therapeutic potential in the deleterious effects of
hypertension. However, recent meta-analyses indicate that
PPARg activators increase the risk of cardiovascular events (Nis-
sen and Wolski, 2007). Therefore, the role of PPARg in cardio-
vascular and cerebrovascular diseases requires further scrutiny.
Better animal models of essential hypertension are needed to
address some questions still outstanding (Lerman et al., 2005).
In particular, models that allow investigators to introduce genetic
manipulations in a temporally defined and cell-specific fashion
would be highly desirable. Furthermore, models that combine
other vascular risk factors, suchasaging,gender, diabetes, hyper-
homocysteinemia,hyperlipidemia, etc.,wouldbeusefulby reflect-
ing more closely the context in which the human disease occurs.
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